NCT03995550View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 3, 2019

Primary Completion Date

January 27, 2020

Study Completion Date

July 16, 2020

Conditions
Healthy
Interventions
DRUG

LEO 142397

A compound in development by LEO Pharma A/S

DRUG

Placebo

Placebo

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit Ltd., Leeds

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY